Alnylam Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Capital World Investors has disclosed a beneficial ownership of 10,916,799 shares, representing 8.2% of the outstanding common stock of Alnylam Pharmaceuticals, Inc.
NASDAQ
FMR LLC, through its affiliates, has reported beneficial ownership of 11.0% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.35% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has reported zero beneficial ownership in Alnylam Pharmaceuticals Inc. common stock following an internal realignment on January 12, 2026.
NASDAQ
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.8% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of September 30, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in Alnylam Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G: Capital Research Global Investors Discloses 5.4% Passive Stake in Alnylam Pharmaceuticals
Capital Research Global Investors has reported a 5.4% beneficial ownership stake in Alnylam Pharmaceuticals, Inc., held for ordinary course investment purposes.